Background {#Sec1}
==========

Pulmonary fibrosis (PF) refers to a morphological pattern of interstitial lung disease in which the lung parenchyma is diffusely and irreversibly scarred \[[@CR1]\]. There are many causes, but regardless of etiology, PF results in varying degrees of physiological restriction and impairment in gas exchange. The hallmark symptoms dyspnea, cough and fatigue, limit physical and social activities and substantially impair quality of life (QOL) \[[@CR2], [@CR3]\]. For most patients with PF, dyspnea is the strongest driver of QOL impairment: it forces them to slow down and avoid or give up activities they enjoy \[[@CR4], [@CR5]\].

As PF progresses, many patients develop hypoxemia. In parallel, symptoms---particularly exertional dyspnea and fatigue---increase and physical activity declines. Patients with PF qualify to receive supplemental oxygen therapy (O~2~) if blood oxygen level or peripheral oxygen saturation (SpO~2~) is found to be low while asleep or awake, either at rest or when physically active. The goals of O~2~ are to improve oxygenation (and avert complications of continuous or intermittent hypoxemia), decrease symptoms, increase mobility -- and by extension, improve QOL.

Universally accepted consensus guidelines for idiopathic pulmonary fibrosis (IPF) suggest oxygenation and symptoms should be assessed at diagnosis and every follow-up evaluation \[[@CR6]\]. No one would argue this is good practice for all patients with PF, regardless of etiology. Several indexes and questionnaires exist to quantify dyspnea, but it is unclear how useful they are in the clinical arena. In prior studies, we confirmed the University of California San Diego Shortness of Breath Questionnaire (UCSD) possessed validity to assess dyspnea in research studies of patients with IPF and showed how UCSD scores could be interpreted in a clinical context \[[@CR7], [@CR8]\].

For this analysis, we examined data from an observational cohort of patients with PF enrolled in a longitudinal, pre/post study designed to observe the effects of O~2~ on a range of patient-centered outcomes \[[@CR9]\]. In the longitudinal study, no patients were on O~2~ at enrollment, and all treatment decisions, including whether to prescribe O~2~, were made by patients' treating physicians, not the research team. Over the course of the longitudinal study, some patients were prescribed O~2~; many were not. Regardless, per the longitudinal study protocol, the UCSD was administered to subjects every month, starting at the time of enrollment and continuing to the end of the study. We aimed to achieve three objectives with this analysis: 1) to examine trends in monthly UCSD scores over time up until O~2~ was prescribed; 2) to identify significant predictors of O~2~ prescription from a pool of candidate clinical variables and 3) to improve understanding of the clinical implications of UCSD scores. We hypothesized monthly dyspnea assessments would predict the need for O~2~.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

The methods for the longitudinal study were published previously \[[@CR9]\]. Briefly, between August 2013 and October 2015, patients with PF of any etiology, greater than 18 years of age, not using O~2~ and able to speak and read English, were recruited either from the Interstitial Lung Disease Clinic at National Jewish Health (NJH) or through our study website which is no longer active ([www.pulmonaryfibrosisresearch.org](http://www.pulmonaryfibrosisresearch.org)). Diagnoses were confirmed by review of medical records and high-resolution chest computed tomography scans. For the many subjects followed outside of NJH, scans were mailed to our lab for review. Each subject gave written, informed consent. The study was approved by the NJH Institutional Review Board (HS-2790), and the study is registered on [ClinicalTrials.gov](http://clinicaltrials.gov) (NCT01961362).

Data capture and outcome measures {#Sec4}
---------------------------------

For the longitudinal study, data were collected at four time points: 1) enrollment; 2) 7-10 days prior to initiation of O~2~ (either continuously or with exertion); 3) 1 month after initiation of O~2~; and 4) 9--12 months after initiation of O~2~. In addition, the UCSD was obtained monthly after enrollment. For the primary analyses presented here, data included baseline characteristics and the monthly UCSD questionnaires up to time point 2 in subjects prescribed O~2~ or 15 months (in subjects who were not) among all subjects who completed at least two monthly UCSDs. We used REDCap (<http://projectredcap.org/>) to send and receive via email the UCSD each month.

The UCSD is a 24-item questionnaire with 21 items asking respondents to rate dyspnea while performing physical activities across a range of energy demands and 3 additional items that assess the impact of dyspnea \[[@CR10]\]. UCSD scores range from 0 to 120; higher scores indicate greater dyspnea.

Statistical analyses {#Sec5}
--------------------

Summary statistics were generated for baseline characteristics. To analyze UCSD scores over time, we developed linear mixed effects models using time, baseline UCSD and prescription of O~2~ (or not) as predictors. We included a random intercept for subjects. We assessed the most reasonable covariance structures for the repeated measures and found that unstructured (SAS Proc Mixed type = un) gave the best fit. The model yielded estimates for the parameters and for difference in slope for UCSD score between subjects who were ultimately prescribed O~2~ and those who were not prescribed O~2~ over the first 15 months after enrollment. We displayed plots for observed and predicted UCSD scores over time for the cohort stratified on whether O~2~ was prescribed. For exploratory purposes, we generated linear, spline-interpolated spaghetti plots of UCSD scores for the five subjects who died before being prescribed O~2~. Next, we examined predictors of time-to-O~2~ prescription over the course of the study by using multivariate Cox proportional hazards regression. Here, we included all 43 subjects prescribed O~2~, regardless of whether they had longitudinal UCSD data (i.e., more than one) or not. We first examined gender, age, smoking status, residence in Colorado (or not), IPF diagnosis (versus other), percent predicted forced vital capacity (FVC%), and baseline UCSD score in univariate analyses. Then, we used backward selection to determine a final model. Variables with *p* ≤ 0.2 in univariate analyses were considered for inclusion, and variables with *p* ≤ 0.05 were retained in the model. O~2~ prescription was the event. Subjects were followed to O~2~ prescription or, if they were not prescribed O~2~, then to last UCSD or death when, for this analysis, they were censored. In an exploratory analysis, we examined whether change in UCSD score would predict death regardless of whether O~2~ was prescribed. Here, time-to-death was the outcome and UCSD score was included in the model as a time-varying covariate and O~2~ prescription was included as a binary (yes/no) predictor. All analyses were performed using SAS version 9.3 statistical software (SAS, Inc.; Cary, NC).

Results {#Sec6}
=======

One-hundred ninety-four subjects completed more than one UCSD or were prescribed O~2~. Forty-three were prescribed O~2~ at some point during the longitudinal study, and 166 were not. Of the 43 subjects prescribed O~2~, 28 had analyzable, longitudinal UCSD data. There was no difference in age, gender distribution, proportion with IPF, smoking history or FVC% between subjects with (*N* = 28) and subjects without (*N* = 15) longitudinal UCSD data (data not shown). Table [1](#Tab1){ref-type="table"} shows the baseline characteristics for the cohort stratified on whether O~2~ was prescribed. Compared to subjects not prescribed O~2~, those who were prescribed O~2~ had significantly greater physiological restriction (*p* = 0.008) and dyspnea (*p* \< 0.0001) at enrollment.Table 1Baseline characteristicsPrescribed O2\
*N* = 28Not Prescribed O2\
*N* = 166*P* valueFemale10 (36)83 (50)0.15Age, yrs67.5 ± 7.967.9 ± 9.60.99Smoking Current1 (4)2 (1) Former15 (54)86 (52) Never12 (43)78 (47)0.61State of residence Colorado4 (14)67 (41) New Mexico1 (4)12 (7) Texas3 (11)12 (7) Other20 (71)75 (45)0.03Pulmonary fibrosis IPF20 (71)41 (25) CTD4 (14)62 (37) cHP2 (7)14 (8) FPF1 (4)11 (7) Other1 (11)38 (23)\< 0.0001Surgical biopsy11 (39)59 (36)0.61FVC%67.3 ± 17.577.81 ± 30.3^a^0.008DLCO%52.5 ± 12.964.3 ± 15.4^b^0.0016Enrollment UCSD score38.4 ± 19.622.6 ± 18.7\< 0.0001Duration of follow-up, days270.1 ± 201.5473.6 ± 191.5\< 0.0001^a^ *N* = 156 with FVC within 4 months of enrollment^b^ *N* = 142 with DLCO within 4 months of enrollment*IPF* idiopathic pulmonary fibrosis, *CTD* connective tissue disease-related pulmonary fibrosis, *cHP* chronic hypersensitivity pneumonitis, *FPF* familial pulmonary fibrosis; "Other" includes drug-induced, asbestosis, unclassifiable

In the mixed-effects model that included variables for baseline UCSD score and whether O~2~ was prescribed (Table [2](#Tab2){ref-type="table"}), UCSD scores from subjects prescribed O~2~ rose more steeply than subjects not prescribed O~2~ (slope = 1.18 ± 0.53 vs. 0.24 ± 0.09 points per month, *p* = 0.02). Figure [1](#Fig1){ref-type="fig"} shows spaghetti plots of UCSD scores for subjects prescribed O~2~ (Panel A) or not (Panel B) and a plot of model-generated estimates and confidence intervals for UCSD scores over time (Panel C). We built the same model but limited subjects to the subgroup with a clinical summary diagnosis of idiopathic pulmonary fibrosis (IPF), and the results were similar; among IPF patients prescribed O~2~, the slope was 1.97 ± 0.74 points per month vs. 0.22 ± 0.12 points per month among IPF patients not prescribed O~2~.Table 2Estimates for linear mixed effects modelEstimate ± standard error*p*Intercept1.18 ± 0.680.08Time0.24 ± 0.090.009Prescribed O~2~4.02 ± 1.320.002Baseline UCSD0.90 ± 0.02\< 0.0001O~2~ = supplemental oxygen; UCSD = University of California San Diego Shortness of Breath Questionnaire Fig. 1Panels **a**-**c** UCSD scores over time for subjects prescribed O2 (Panel **a**) or not (Panel **b**). Estimates for UCSD scores from mixed-effects model (Panel **c**). Footnote: In Panel **c**, estimate for subjects prescribed O2 red solid line, and estimate for subjects not prescribed O2 blue solid line. Dashed lines represent 95% confidence bands

Univariate analysis of candidate predictors for time-to-O~2~-prescription are given in Table [3](#Tab3){ref-type="table"}. Subjects who resided in Colorado were less likely to be prescribed O~2~ than subjects who resided in other states. Significant predictors of O~2~ prescription included IPF as the clinical summary diagnosis, lower FVC%, lower DLCO% and higher UCSD score at enrollment. The final multivariate model, after backward variable selection, included two predictors: 1) Baseline UCSD score, hazard ratio \[HR\] = 1.04, (1.02, 1.05), *p* \< 0.0001; and 2) IPF clinical summary diagnosis, HR = 4.41, (2.26, 8.61), *p* \< 0.0001. For interest, we forced baseline UCSD, IPF clinical summary diagnosis and baseline FVC% into a model, used no selection method and observed the following results: 1) Baseline UCSD score, HR = 1.04, (1.02, 1.06), p \< 0.0001; 2) IPF clinical summary diagnosis, HR = 4.85, (2.19, 10.74), p \< 0.0001; and 3) baseline FVC%, HR = 0.99 (0.97,1.01), *p* = 0.27).Table 3Predictors of being prescribed O~2~ ^a^Hazard Ratio (95% confidence limits)*p*Female0.53 (0.28, 1.00)0.05Age, yrs1.00 (0.97, 1.03)0.99Ever-smoker1.62 (0.87, 3.04)0.13Reside in Colorado0.24 (0.10, 0.61)0.003IPF3.57 (1.93, 6.61)\< 0.0001FVC%^b^0.95 (0.93, 0.98)0.0003DLCO%^b^0.96 (0.93, 0.99)0.003UCSD at enrollment1.03 (1.01, 1.04)\< 0.0001^a^For all 43 subjects prescribed O2, regardless of whether they completed UCSD prior to O2 prescription^b^within 4 months of enrollment; IPF = idiopathic pulmonary fibrosis; FVC% = percent predicted forced vital capacity; UCSD = University of California San Diego Shortness of Breath Questionnaire

Five subjects died prior to being prescribed O~2~. Their observed median UCSD score at enrollment was 35.1 (22.0, 46.9). Their observed UCSD scores rose a median 36.0 (−9.9, 41.0) points over a median 295 (268, 319) days from enrollment to last UCSD collection. In a mixed-effects model that included variables for baseline UCSD score, subjects who died had slopes for UCSD scores that rose (3.8 ± 0.5 points/month) significantly more sharply than either subjects who were prescribed O~2~ (*p* \< 0.0001) or subjects who were not prescribed O~2~ and survived (p \< 0.0001). Spaghetti plots of UCSD scores over time for the five subjects who died are in the Additional file [1](#MOESM1){ref-type="media"}: Figure S1). In the exploratory survival analysis that included 10 subjects who died (5 prior to and 5 after O~2~ was prescribed), while adjusting for whether O~2~ was prescribed, any five-point increase in UCSD score was associated with a greater than 40% increase in the risk of death (HR = 1.44; 95% confidence limits 1.21, 1.73; *p* \< 0.0001).

Discussion {#Sec7}
==========

In this study, we analyzed dyspnea over time in a cohort of patients with PF enrolled in a longitudinal study. Compared with subjects who were not prescribed O~2~, those who were had more severe dyspnea at enrollment and a steeper increase in dyspnea scores over time.

To our knowledge, this is the first study in which such a rich trajectory of dyspnea has been plotted in patients with PF. In most studies and clinical trials, if dyspnea is assessed, it is done at 3-6 month intervals. Martinez and colleagues reported on UCSD scores collected every 12 weeks from 168 subjects in the placebo group of a randomized, controlled trial of interferon-ɣ1b for IPF \[[@CR11]\]. They observed that mean UCSD scores rose minimally, from 45.1 at baseline to 46.8 at 72 weeks. However, among 36 subjects in the sample who died---although there was substantial variability---UCSD scores often rose sharply in the 12 weeks before death. The authors did not quantify these results, but a figure in their manuscript showing spaghetti plots for UCSD scores nicely displays the trends.

In our study, dyspnea scores from 4 of the 5 subjects who died before being prescribed O~2~ rose sharply in the 4-8 weeks prior to death. Among the 10 total subjects who died in the longitudinal study (5 before and 5 after being prescribed O2), an increase in dyspnea was associated with a 40% increase in the risk of death any time during the follow-up period. Unfortunately, we do not have data on their causes of death, how practitioners dealt with patients' worsening symptoms---or whether they were even aware. Collecting quantitative dyspnea data more frequently from PF patients could potentially, like daily spirometry \[[@CR12]\], alert patients and practitioners to PF acceleration, prompt urgent evaluation and trigger timely intervention. Future studies should examine whether dyspnea scores---and changes in them---alter therapeutic approaches and determine if they can be used to more accurately predict survival and other outcomes in patients with PF.

The results from this study reveal dyspnea predicts the outcome "being prescribed O~2~", something perceived by PF patients and their caregivers as a major setback---as a potentially activity-limiting and socially constraining intervention that impacts quality of life \[[@CR3], [@CR4]\]. We can extrapolate our results to add clinical context: using the parameter estimate for UCSD at enrollment from the univariate Cox proportional hazards model (0.026), any 8-point increase in enrollment UCSD score (a point estimate for it's minimum important difference \[[@CR7]\]) is associated with a 23% increased risk of being prescribed O~2~ in the ensuing 15 months. The protective effect of living in Colorado is due to them being enrolled in the study earlier than other subjects in the course of illness.

In previously published work from our lab, we created a 21-item UCSD Dyspnea Ruler that can also put UCSD scores in a clinical context \[[@CR8]\]. To use the Ruler, one sums the responses from the first 21 items on the UCSD. These items ask respondents to rate their dyspnea severity while performing physical activities that span a range of energy demands (determined by the activity's metabolic equivalents or METS). As PF progresses, respondents become more likely to rate dyspnea as worse for a given activity. For example, a patient with mild PF might rate their dyspnea as mild when walking up a flight of stairs, but if PF progresses, their dyspnea rating for this roughly 8-MET activity would increase. We calculated 21-item UCSD scores for subjects in the current study: the Dyspnea Ruler would predict that, at baseline, subjects not prescribed O~2~ during the course of the study would have described moderate dyspnea for the UCSD item "How short of breath do you get walking up a hill?" (i.e., they would have an equal probability of responding "2" or "3" on the 0-5 scale). Meanwhile, at baseline, subjects prescribed O~2~ during the course of the study would describe the same level of moderate dyspnea while doing a less strenuous task, such as washing a car (or carrying a light \[e.g., 15-pound\] load on level ground) \[[@CR13]\]. By the time they were prescribed O~2~, they would have described moderate dyspnea with even less strenuous activities, like walking downstairs, clearing the table after a meal, or walking leisurely to a neighbor's house for social reasons \[[@CR13]\].

We observed the two strongest, independent predictors of being prescribed O~2~ were dyspnea severity at enrollment and an IPF clinical summary diagnosis. In a model controlling for enrollment UCSD and FVC%, subjects with IPF were over four times more likely than subjects with other diagnoses to be prescribed O~2~. The fact that dyspnea increased significantly in many (but not all) subjects with IPF is not surprising. That subjects with IPF were more likely than other subjects to have been prescribed O~2~ is reassuring. To us, it signals that practitioners are recognizing the likelihood of disease progression and hypoxemia in patients with IPF; and they are assessing/reassessing oxygen status and responding to abnormal results. Whether O~2~ prescription translates to improvements in the way patients with IPF (or PF of any cause) feel or function, or in how long they survive, are presently questions without answers and topics for other studies.

This observational study has limitations. In an attempt to offer enrollment to as many patients as possible, we designed a nationwide study in which patients were not required to travel, even to their local physician or medical facility. This made data collection and diagnosis confirmation challenging but not impossible. We did our best to review all available medical records, including chest computed tomography images, to assess the fidelity of diagnoses recorded in subjects' medical records. We did not request surgical biopsy slides for review. Having incomplete historical data could have introduced misclassification bias; however, because subjects were enrolled prior to being prescribed O~2~, if present, misclassification would have been nondifferential---equally present in both subgroups (prescribed O~2~ and not prescribed O~2~). Nondifferential misclassification would bias toward the null, diluting between-groups differences.

Of 300 subjects enrolled, only 194 had more than one monthly UCSD data collection, and of these, O~2~ was prescribed in 28. Despite the low number of subjects receiving O~2~, administering the UCSD monthly yielded a large number of data points, giving precision to many model estimates---like change in UCSD over the first 12 months.

The research team played no role in determining whether or when subjects were prescribed O~2~. This lack of autonomy over O~2~ prescription precludes us from drawing firm conclusions on precisely when and whether patients needed O~2~, how the determination of need for O~2~ was made, or when or how it was prescribed if needed. We were merely collecting data before and after. The real value of this analysis lies in its "real-world", patient-centered design and the rich dataset resulting from monthly dyspnea data collection.

Many other factors, both measurable and unmeasurable, likely affected when and whether O~2~ was prescribed. Measurable, patient-related characteristics for which we have no data include insurance coverage, economic status, access to care, proximity to O~2~ suppliers, and patients' values and preferences for their personal health and healthcare. Among others, unknown practitioner-related factors include their beliefs and judgments about the potential merits of O~2~ for patients with PF.

Conclusion {#Sec8}
==========

Among patients with PF, dyspnea levels are associated with timing of O~2~ prescription. Baseline dyspnea levels can predict the need for O~2~ in the near future. Controlling for the severity of physiological restriction and dyspnea level, patients with IPF are more likely to be prescribed O~2~ than patients with PF from other causes. Research is needed to better understand this phenomenon, to determine the effects of O~2~ on how patients with PF feel and function, and to ascertain whether frequent dyspnea assessments could be used to alter therapeutic interventions and outcomes in PF.

Additional file {#Sec9}
===============

Additional file 1:Spaghetti plots of UCSD scores for five subjects who died before being prescribed supplemental oxygen. (DOCX 40 kb)
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